Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Glycine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLRA1 | P23415 | 1/20 | 0.46 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.46 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | PEPD | P12955 | 1/20 | 0.32 |
| ▸ | GABRR1 | P24046 | 5/20 | 0.32 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.32 |
| ▸ | PLG | P00747 | 1/20 | 0.31 |
| ▸ | PLAT | P00750 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL204179 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL6131906 | 0.74 | — | — | |
| Glycine SCHEMBL1101471 | 0.71 | — | — | |
| Glycine SCHEMBL28397381 | 0.69 | GLRA1 (0.62) | GLRA1SLC6A9OR51E2PEPDGABRR1 | |
| Glycine SCHEMBL2173384 | 0.69 | GLRA1 (0.53) | GLRA1SLC6A9OR51E2PEPDGABRR1 | |
| Glycine SCHEMBL3640989 | 0.67 | GLRA1 (1.00) | GLRA1SLC6A9OR51E2GABRR1GABRR2 | |
| Glycine SCHEMBL6675874 | 0.67 | GLRA1 (1.00) | GLRA1SLC6A9OR51E2GABRR1GABRR2 | |
| Glycine SCHEMBL391786 | 0.67 | GLRA1 (1.00) | GLRA1SLC6A9OR51E2GABRR1GABRR2 | |
| Glycine SCHEMBL2116443 | 0.67 | — | — | |
| Glycine SCHEMBL93765 | 0.67 | GLRA1 (1.00) | GLRA1SLC6A9OR51E2GABRR1GABRR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773791-B1 | PYRROLOTRIAZINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2010-09-22 | — | — | EP | disclosed |
| EP-1773791-A4 | PYRROLOTRIAZINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2009-08-26 | — | — | EP | disclosed |
| EP-1773791-A1 | PYRROLOTRIAZINE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2007-04-18 | — | — | EP | disclosed |
| US-7102003-B2 | Pyrrolotriazine compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-05 | — | — | US | disclosed |
| WO-2006007468-A1 | PYRROLOTRIAZINE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-01-19 | — | — | WO | disclosed |
| US-20060014745-A1 | Pyrrolotriazine compounds | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014745-A1 | Pyrrolotriazine compounds | ERBB2, ERBB4, EGFR | GLRA1 2304/4885SLC6A9 4097/4885OR51E2 4362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.